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Background: The aim of this study was to evaluate the uptake and -washout of I-123 meta-
iodobenzylguanidine (MIBG), reflecting norepinephrine metabolism, in the lungs in
patients with sarcoidosis.
Methods: Lung I-123 MIBG kinetics was assessed in 43 patients with sarcoidosis. The range
of disease duration was 1–16 years (median: 3 years). Thirteen patients had radiographic
stage 0–I, 30 patients had radiographic stage II–IV. Serological clinical parameters and
small fibre neuropathy, as assessed by temperature threshold testing (TTT) were measured
in 39/43 patients. 31/39 patients had an abnormal TTT. Eleven healthy controls
participated in this study. Both dual head planar and dual headed SPECT images of the
thoracic regions were made. The uptake of I-123 MIBG and the washout percentage were
calculated in sarcoidosis patients and compared with the healthy persons.
Results: Lung I-123 MIBG uptake in patients with sarcoidosis did not differ from controls.
The lung washout of I-123 MIBG was significantly (pp0.01) decreased in sarcoidosis.
Remarkably this was most clearly seen in patients with an abnormal TTT and in patients
with more advanced radiographic pulmonary involvement (radiographic stages II–IV) but
not in patients with decreased lung function (FVCo80% or DLCOo80%).
Conclusion: The inflammatory process of the lungs in sarcoidosis seems not to affect
pulmonary vasculature. In sarcoidosis decreased lung washout of I-123 MIBG might, at least
partly, be explained by sympathetic autonomic nerve dysfunction. Future studies are
needed to explore the clinical relevance of this observation.
& 2007 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
of Respiratory Medicine, University Hospital Maastricht, P.O. Box 5800, 6202 AZ Maastricht,
; fax: +31 84 223 4007.
.nl (M. Drent).
ARTICLE IN PRESS
Lung-uptake and -washout of MIBG in sarcoidosis 65Introduction
Sarcoidosis is a disseminated granulomatous disease of
unknown origin. Granulomas are clusters of macrophages,
lymphocytes and cells called multinucleated giant cells.
Depending on the organs involved and the severity of
granulomatous inflammation, patients suffer from a broad
range of symptoms. The disease can involve any organ of the
body in any location, but sarcoidosis is most frequently
found in the lungs.1 Granulomas can appear in the lungs on
the walls of the alveoli or on the walls of the bronchioles.
They also can appear in the lymph nodes in the chest,
causing them to enlarge. Besides respiratory symptoms such
as coughing and dyspnoea, patients often suffer from
apparently non-specific symptoms such as fatigue and pain.
These symptoms were found to be related to small fibre
neuropathy (SFN) with autonomic involvement.2
Iodine-123 meta-iodobenzylguanidine (MIBG), an analo-
gue of norepinephrine (NE), shares the same uptake, storage
and release mechanism as NE in neurons.3–5 As I-123 MIBG
shares several metabolic pathways with NE in the adrenergic
nerve terminals, it can be used as a tracer for imaging the
adrenergic nerve system of the heart. Lung uptake of I-123
MIBG is by a temperature sensitive saturable sodium-
dependent energy active transporter system located in the
endothelium cell membrane.6–9 Although autonomic nerves
dominate the lung tissue, including smooth muscles, mucous
glands and blood vessels, I-123 MIBG uptake by nerve ending
is probably negligible.6 Moreover, lung uptake, in contrast to
heart tissue, of catecholamines is not reduced by chemical
sympathectomy,10,11 indicating that the uptake is primarily
regulated by an extra-neuronal mechanism.
In earlier observations it has been discussed, however,
that washout rate of lung I-123 MIBG activity could be an
indicator of pulmonary adrenergic activity.5,12
Recently we reported visual I-123 MIBG uptake defects of
the heart in about one-third of patients with sarcoidosis
suggesting autonomic dysfunction.13 During that study
abnormal I-123 MIBG activity in the lungs of sarcoidosisTable 1 Summary of characteristics of the studied sarcoidosis
Controls (n ¼ 11) Sa
Age (years) 45 (25–56) 39
Sex (male/female) 11/0 28
Smoking (yes/no) 0/11 1/
Time since diagnosis (years) 4 (
Prednisolone (yes/no) 0/11 19
CXR (O/I/II/III/IV) 5/
Hs-CRP (ref.: 0.26–7.24mg/L)
ACE (ref.: 9–25) 2
sIL-2R (ref.: 241–846 kU/L) 7
FVC (%) 10
FEV1 (%) 9
DLCO (%) 8
Data are expressed as mean7standard deviation or with range in par
to DeRemee (0–III), adding stage IV, the end stage of lung fibrosis
converting enzyme. sIL-2R: soluble Interleukin-2-receptor. FVC (%): fo
forced expiratory volume in 1 s expressed as percentage of normal.
expressed as percentage of normal.patients was observed. In this study, serial I-123 MIBG
images of the lung were acquired to evaluate whether
observation of this variable lung uptake in more detail could
improve the apprehension of the role of the metabolism of
catecholamines in sarcoidosis.
Materials and methods
Study population
Between March 2003 and April 2005, 64 patients admitted to
the Sarcoidosis Management Center Maastricht, which serves
as a tertiary referral centre for sarcoidosis patients in the
Netherlands, had a I-123 MIBG scintigraphy. All patients were
diagnosed with sarcoidosis based on consistent clinical
features and bronchoalveolar lavage (BAL) fluid analysis
results, according to World Association of Sarcoidosis and
Other Granulomatous disorders (WASOG) guidelines.14
Furthermore, most (n ¼ 50) had biopsy proven non-caseating
epitheloid cell granuloma. Exclusion criteria were the use of
medication that possibly influences I-123 MIBG uptake or -
washout (n ¼ 18)15 and diabetes mellitus (n ¼ 3).12,16
Finally, 43 patients (28 (65%) men and 15 (35%) women)
were included in this study. The median age was 45 years
(range: 28–70). The duration of illness ranged from less than
1 year to 16 years (median: 3 years). The control group
consisted of 11 healthy male volunteers with a mean age of
39 years (range: 25–56). None of the control subjects was
taking any medications or had a history of diabetes, heart
disease, chronic obstructive pulmonary disease (COPD) or
hypertension. For characteristics of study population, the
excluded patients and control group, see Tables 1 and 2.
I-123 MIBG data acquisition
All subjects received an oral dose of potassium perchlorate
(200mg) once a day, starting the day before scintigraphy
and continued for 2 days in order to block uptake by thepatients, the control group and the excluded patients.
rcoidosis patients (n ¼ 43) Excluded patients (n ¼ 21)
(28–70) 48 (27–65)
/15 14/7
42 1/20
0–16) 4 (0–18)
/24 13/8
9/16/11/2 5/5/7/3/1
7.1714.1 7.1714.4
1.6710.9 20.8711.0
317592 7597667
0.4720.4 88.2718.5
2.7720.7 82.4718.9
5.7714.6 76.2723.6
entheses if appropriate. CXR: chest radiographic stage according
. Hs-CRP: high-sensitivity C-reactive protein. ACE: angiotensin
rced vital capacity expressed as percentage of normal. FEV1 (%):
DLCO (%): diffusion capacity of the lung for carbon monoxide
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Table 2 Exclusion criteria of the sarcoidosis patients.
Excluded
patients
(n ¼ 21)
Diabetes mellitus 3
Opiates 4
Tricyclic antidepressant 1
ACE inhibitors 6
Beta-blockers 7
Dopaminergic neurons blocking agents 2
Some patients used more than one drug.
G.J. Jonker et al.66thyroid. After a slow intravenous injection of a mean dose of
193.4MBq/5.22mCi (range: 168–235.6MBq/4.54–6.37mCi)
I-123 MIBG (Amersham-GE, Eindhoven, the Netherlands),
anterior and posterior planar images were made of the
thorax and upper abdominal region using a dual detector
gamma camera (Siemens Multispect-2) equipped with a
medium-energy general-purpose collimator. The exact time
of injection of the radiopharmaceutical as well as the
injected dose were recorded. Images were acquired over a
5min interval and stored in a 128 128 matrix. A symmetric
15% energy window centred on the 159 keV photon peak of I-
123 was used. All studies started with the acquisition during
5min of a transmission scan using a Co-57 flood source (20%
window, 122 keV photon peak). Images were made 30 and
240min after injection.
I-123 MIBG data analysis
Counts were expressed as the geometric mean of the
anterior and posterior views after correction for acquisition
time, decay and attenuation. Regions of interests were
placed over the, mediastinum, and the mid zone of the left
and right lung. The average counts expressed as percentage
of the injection dose per pixel were calculated on the early
(30min) and delayed images (240min). All values were
corrected for the exact time of acquisition by fitting a single
exponential curve. The washout percentage was calculated
as follows: I-123 MIBG washout % ¼ (early uptakedelay
uptake/early uptake 100).
Serological measurements
From all patients blood samples were taken and serum was
stored at 20 1C until actual measurement, which occurred
for all samples within 2 months after storage.
Soluble Interleukin-2-receptor (sIL-2R) was determined by
a two-site chemo luminescent enzyme immunometric assay
on the IMMULITE Automated Analyser (Diagnostic Product
Corporation, Los Angeles, CA, cat. no. LKIP1). The detection
limit of the assay is 50 kU/L, and the measuring range is
50–7500 kU/L. The within- and the between-run imprecision
of the assay was below 7.2%, and the reference interval for
sIL-2R was 241–846 kU/L.
High-sensitivity C-reactive protein (Hs-CRP) was mea-
sured by particle enhanced immunonephelometry on the BNProspec (Dade Behring). The detection limit for hs-CRP is
0.175mg/L and the measuring range is 0.175–1100mg/L,
depending on the dilution (Dade Behring, Liederbach
Germany, N Hs CRP; cat. no. OQIY 13; supplement reagent
OUMU). The reference interval was 0.26–7.24mg/L.
Serum angiotensin converting enzyme (ACE) was mea-
sured by colorimetric method (Fujirebio Inc., Tokyo, Japan,
cat. no. FU 116). ACE acts on a substrate p-hydroxybenzoyl-
glycyl-L-hystidyl-L-leucine and separates p-hydroxybenzoyl-
glycine, which is converted in two subsequent reactions
into quinoneimine dye. The absorbance of the quinoneimine
dye is measured at 505 nm to evaluate ACE activity. The
imprecision of the ACE assay was below 5.6%, and the
reference interval of ACE was 9–25U/L.Lung function testing
Lung function measurements, including forced expiratory
volume in 1 s (FEV1) and forced vital capacity (FVC), were
measured with a pneumotachograph (Masterlab, Jaeger,
Wu¨rzburg, Germany). The diffusing capacity for carbon
monoxide (DLCO) was measured by the single breath method
(Masterlab, Jaeger, Wu¨rzburg, Germany). Values were
expressed as a percentage of predicted.17 All values of 80%
and higher were considered normal.Chest radiograph
Chest radiographs were graded according to the radio-
graphic staging of DeRemee (0–III), adding stage IV, the end
stage of lung fibrosis.14,18 A radiologist, blinded to the
patient’s history, performed all interpretations.Temperature threshold testing
Temperature sensation threshold measuring was used to
assess function of small calibre sensory fibres. This method
has been reviewed by Antiskid.19 Temperature threshold
testing (TTT) was done by means of a Medoc TSA-2001
device (Medoc, Ramat Yishai, Israel). Thresholds for warm
and cold sensation were determined on the hand and on the
dorsum of the foot on both sides using the method of levels
(MLE) and the method of limits (MLI) as described earlier.20
Normative data according to Yarnitsky were used.21 Tem-
perature sensation was considered abnormal if at least on
one side both MLE and MLI testing resulted in Z values
exceeding 2.5 (above the 99th percentile).20Statistical procedure
The Kolmogorov–Smirnov test showed that washout was
normally distributed. Independent sample t-tests were per-
formed to examine mean scores for washout of the lungs
between sarcoidosis patients and control persons. This analysis
was also performed between sarcoidosis patients with a small
fibre neuropathy and control persons. A w2 test was done with
temperature threshold and subgroups of radiographic stages. A
p-value of 0.05 was considered statistically significant. All
analyses were done with SPSS version 12.1.
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Uptake in the lungs did not differ between the controls and
the study group (see Table 3). The I-123 MIBG uptake in the
mediastinum and the washout from the mediastinum did not
differ between all groups. Washout from the lungs, however,
was reduced in the studied sarcoidosis patients. The mean
I-123 MIBG-washout (of right and left lung) was 37.0% in
controls whereas it was only 28.8% in sarcoidosis patients
(po0.005; see Table 3). For sarcoidosis patients with an
abnormal TTT, an indication for small fibre neuropathy, the
difference in washout was even more prominent (po0.001;
see Table 4). In sarcoidosis patients with a normal TTT, the
washout was also lower compared to controls (po0.05) but
higher than in sarcoidosis patients with an abnormal TTT
(po0.05; see also Table 4).
Sarcoidosis patients with more advanced pulmonary
interstitial involvement (radiographic stages II–IV) had also
a more prominent reduction of lung washout as compared to
controls (po0.001, see Table 4). In patients withoutTable 3 Pulmonary uptake and -washout of I-123 MIBG in cont
Controls (n ¼ 1
Right lung 30 1.25 10270
Right lung 240 0.77 10270
Left lung 30 1.17 10270
Left lung 240 0.75 10270
Washout right lung 38.4376
Washout left lung 35.6175
Mean washout right and left lung 37.0275
Data are expressed as mean7standard deviation. Right/left lung 30:
30min. Right/left lung 240: planar quantification of I-123 MIBG uptak
MIBG lung washout expressed as percentage of lung uptake after 30m
and left lung.
po0.005 compared to controls.
ypp0.01 compared to controls.
Table 4 Pulmonary washout of I-123 MIBG in controls and sarc
Controls
(n ¼ 11)
Sarcoidosis patien
Normal TTT
(n ¼ 12)
Washout right lung 38.4376.04 31.0477.38z
Washout left lung 35.6175.84 31.6877.13
Mean washout right
and left lung
37.0275.98 31.3077.24y
Data are expressed as mean7standard deviation. TTT: temperatu
washout expressed as percentage of lung uptake after 30min. Mean w
po0.005 compared to controls.
ypo0.05 compared to chest X-ray stages II–IV and controls.
zpp0.01 compared to controls.
ypo0.05 compared to controls and sarcoidosis patients with an ab
zpo0.05 compared to controls.
Jpp0.001 compared to controls.radiological signs of parenchymal involvement (radiographic
stages 0 and I), the washout was also lower compared to
controls (po0.05) but higher than in patients with radio-
graphic stages II–IV (po0.05).
In the sarcoidosis group, no significant differences for lung
washout between sexes or patients who used prednisolone
were found. There was also no correlation between lung
washout and use of prednisolone, serological parameters
(hs-CRP, ACE and sIL-2R) or lung function test results.
Moreover, we compared the group with a FVC o80% (n ¼ 5)
to those with a FVC above 80% (n ¼ 38), as well as the group
with a DLCO of o80% (n ¼ 14) to the group with a DLCO
above 80%.29 This revealed no statistical significant differ-
ences (data not shown).Discussion
As I-123 MIBG, like NE, is retained in the lungs by an
active transporter system located in the endothelium cellrols and sarcoidosis patients.
1) Sarcoidosis patients total (n ¼ 43)
.16 102 1.32 10270.38 102
.12 102 0.92 10270.26 102
.18 102 1.17 10270.25 102
.12 102 0.83 10270.16 102
.04 29.2678.90
.84 28.3678.84y
.98 28.8178.83
planar quantification of I-123 MIBG uptake in right/left lung after
e in right/left lung after 240min. Washout right/left lung: I-123
in. Mean washout: average of I-123 MIBG lung washout of right
oidosis patients.
tsz
Abnormal TTT
(n ¼ 31)
Chest X-ray
stages 0–I
(n ¼ 14)
Chest X-ray
stages II–IV
(n ¼ 29)
28.4979.28 31.9877.38y 28.0479.37
27.3879.27z 32.4777.01 26.5879.16
27.9479.22J 32.2377.18y 27.3179.21J
re threshold testing. Washout right/left lung: I-123 MIBG lung
ashout: average of I-123 MIBG lung washout of right and left lung.
normal TTT.
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G.J. Jonker et al.68membrane, lung uptake of I-123 MIBG is thought to
represent pulmonary vascular surface area and the func-
tional integrity of pulmonary endothelial cells.6,7,9,22,23 In
various conditions, a correlation between I-123 MIBG uptake
in the lungs and the development of pulmonary damage has
been shown.24–26 In these studies, it was very likely that the
damaging process in the lungs was the result of a
pathophysiological process that is located in the pulmonary
endothelium.
This study is the first that reports normal I-123 MIBG
uptake in the lung in sarcoidosis patients. Although
sarcoidosis belongs to the group of lung diseases that are
characterized by chronic inflammation, sometimes with
progressive fibrosis of the pulmonary interstitium, the
normal I-123 MIBG uptake makes it tempting to speculate
that the inflammatory process that is involved in sarcoidosis
does not affect pulmonary vasculature.
In our study, there was a significant reduction of I-123
MIBG washout from the lungs in sarcoidosis. This reduction
of washout is most clearly seen in patients with an abnormal
TTTand in patients with radiographic evidence of pulmonary
damage (e.g. radiographic stages II–IV). This is illustrated in
Figure 1 where a 35-year-old male patient is shown with
severe fibrosis. He had no relevant medical history, and
presented with cough, dyspnoea, exercise limitation and
palpitations due to ventricular arrhythmias. He had an
abnormal TTT. In this patient, pulmonary uptake is normal
but pulmonary washout is markedly reduced. Although in
previous studies, a reduction of pulmonary I-123 MIBG
washout has been reported in various conditions such as
diabetes mellitus, congestive heart failure, COPD and
fibrosis,5,12,27–30 it is not fully clear how this phenomenon
should be explained. It has been postulated that the
reduction of washout is the result of pulmonary vascular
damage12,27 or is the result of autonomic (sympathetic)
dysfunction.5,27 However, other mechanisms could not be
ruled out.
As in our study lung uptake of I-123 MIBG was completely
normal, surface area and integrity of pulmonary vasculature
must be considered normal, it is, in our opinion, therefore,Figure 1 Patient with severe pulmonary as well as cardiac sarcoid
enlarged hilar lymph nodes and parenchymal damage in both lungs (
of
123
I-MIBG 240min after injection shows areas with increase
123
I-MIvery unlikely that a vascular mechanism would be an
explanation for the decreased pulmonary washout. Re-
cently, a vascular mechanism has also been shown unlikely
in a study by Suga et al.24 who found an even enhanced
washout in patients with endothelial damage.
It has been postulated before that the pulmonary washout
of MIBG could possibly be related to the distribution and
functional status of sympathetic nerves29 and that there is a
relation between MIBG accumulation in the lung and
sympathetic nervous dysfunction.5 The fact that the reduc-
tion of lung I-123 MIBG washout in our study is most clearly
seen in patients with an abnormal TTT indeed seems to
suggest that autonomic nerve dysfunction plays a role. An
abnormal TTT is indicative of a systemic autonomic nerve
dysfunction as has been reported previously.20,31
A decreased lung washout has also been found in diabetic
patients, especially in patients with postural hypoten-
sion.5,12 This seems to strengthen the hypothesis that
autonomous nerve dysfunction plays a role in decreased
lung I-123 MIBG washout.
With an intact endothelial uptake mechanism, the uptake
in the lungs of I-123 MIBG only depends on its availability in
the pulmonary circulation. In the presence of autonomic
nerve dysfunction, there is less NE and I-123 MIBG taken up
in the storage vesicles of nerve endings, so there is more of
it available in the extravesicular compartment. The in-
travesicular I-123 MIBG is retained for a prolonged period,
while the extravesicular I-123 MIBG shows rapid decrease.
As I-123 MIBG, unlike catecholamines, is not metabolized in
the lungs,32,33 so there is more I-123 MIBG available in the
circulation and it can be retained longer through the
pulmonary endothelial receptors.5,34 This results in a
reduction of the calculated I-123 MIBG washout. The
reduced pulmonary washout could by this mechanism be
explained as an indirect effect of autonomic sympathetic
dysfunction.
The reduction of I-123 MIBG washout was also more
prominent in patients with radiological stages II–IV as
compared to the whole group. In our view this means that
apart from the autonomic dysfunction, there must be someosis, as seen on chest X-ray, showing radiographic stage II with
A), and confirmed on the HRCT thorax (B). Planar anterior image
BG activity in both lungs (C).
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Lung-uptake and -washout of MIBG in sarcoidosis 69additional explanation. It has been stated above that
pulmonary vascular damage is not a likely mechanism that
is involved in the inflammatory process of sarcoidosis as in
contrast of the fibrosing process in IPF,29 in Beceht’s
disease28 or in COPD.30 As the reduction of pulmonary
I-123 MIBG washout is not seen in patients with lung-
functional signs of fibrosis (reduced FVC and/or reduced
TLCO) we assume that this additional mechanism is not
related to the fibrosis itself but to a non-vascular mediated
process that initiates the fibrosis in the lungs.
Our study was insufficiently powered to prove a statistical
significant difference between patients with- and without an
abnormal TTT and between patients with and without
radiographic evidence of pulmonary involvement which
would further have stressed the role of autonomic dysfunc-
tion and radiographic pulmonary involvement in MIBG
washout.
One of the limitations of our study is that our control
group consisted of only males and, although mean age did
not differ much, the study groups were not matched with
respect to age. We assumed, based on one earlier study35 no
gender differences in I-123 MIBG metabolism. Earlier it has
been shown that uptake of I-123 MIBG has no significant
correlation with age but pulmonary washout decreases with
age.35 We are aware that our assumption on gender and the
slight age difference between both study groups might limit
the value of the study.Conclusion
The I-123 MIBG washout from the lungs is decreased; this is
partly the indirect effect of sympathetic autonomic nerve
dysfunction. Apart from the autonomic nerve dysfunction,
there must be an additional explanation for the decreased
lung washout, probably related to a non-vascular damaging
process of the lungs but not the fibrosis itself. The
inflammatory process in sarcoidosis seems not to be related
to pulmonary vasculature.Conflict of interest
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